Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Adjuvant Trial in Pancreatic Cancer Comparing 5FU and D-L-Folinic Acid vs. Gemcitabine.

Next Previous
Trial Profile

Phase III Adjuvant Trial in Pancreatic Cancer Comparing 5FU and D-L-Folinic Acid vs. Gemcitabine.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Fluorouracil; Folinic acid
  • Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma; Periampullary cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ESPAC-3

Most Recent Events

  • 10 Apr 2021 Results assessing digital quantification of GATA6 immunohistochemistry association with overall survival and pancreatic adenocarcinoma specimens were obtained from patients enrolled in two clinical studies: ESPAC-3 and ESPAC-4 presented at the 112th Annual Meeting of the American Association for Cancer Research
  • 08 Mar 2018 Results of an analysis assessing the intra-tumoural dihydropyrimidine dehydrogenase expression status in patient population from this trial (n= 238), published in the British Journal of Cancer.
  • 11 Jul 2012 Results published in JAMA: the Journal of the American Medical Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top